Exelixis
EXEL
#1695
Rank
โ‚น840.88 B
Marketcap
โ‚น2,944
Share price
-3.83%
Change (1 day)
51.92%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น24.05. In 2022 the company made an earnings per share (EPS) of โ‚น48.38 a decrease over its 2021 EPS that were of โ‚น62.81.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-52.05%
2022โ‚น48.38-22.97%
2021โ‚น62.81100%
2020โ‚น31.41-65.09%
2019โ‚น89.97-53.91%
2018โ‚น195.22333.96%
2017โ‚น44.99-260.61%
2016-โ‚น28.01-58.75%
2015-โ‚น67.90-42.45%
2014-โ‚น117.985.3%
2013-โ‚น112.0443.48%
2012-โ‚น78.09-264.29%
2011โ‚น47.53-165.88%
2010-โ‚น72.15-32.54%
2009-โ‚น106.95-17.65%
2008-โ‚น129.8775.86%
2007-โ‚น73.85-25.64%
2006-โ‚น99.318.33%
2005-โ‚น91.67-42.86%
2004-โ‚น160.4230.34%
2003-โ‚น123.08-5.23%
2002-โ‚น129.87-0.65%
2001-โ‚น130.72-51.88%
2000-โ‚น271.62

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น297.14 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น269.94 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น154.62 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น336.97 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,201 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,196 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น157.88 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น848.80-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น71.30-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA